The Neuroprotective Effect of the Forebrain-S elective NMD A Antagonist CP101,606 upon Focal Ischemic Brain Damage Caused by Acute Subdural Hematoma in the Rat

Tsuchida, Eiji; Rice, Melody R.; Bullock, Ross

doi:10.1089/neu.1997.14.409

Cited by 40 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the lesion size increased further despite only moderate intracranial hypertension and hypoperfusion in most rat models. 13 Indeed, the ischemic area can increase even if cerebral perfusion pressure is normalized. 10 Thus, better treatment options are needed in order to prevent secondary ischemic cell death.…”

Section: Discussionmentioning

confidence: 99%

The neuroprotective effect of diazoxide is mediated by mitochondrial ATP-dependent potassium channels in a rat model of acute subdural hematoma

Nakagawa

Wajima

Tamura

et al. 2013

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The neuroprotective effect of diazoxide is mediated by mitochondrial ATP-dependent potassium channels in a rat model of acute subdural hematoma

Nakagawa

Wajima

Tamura

et al. 2013

Journal of Clinical Neuroscience

View full text Add to dashboard Cite

“…In this field the NR2B-selective type of non-competitive antagonists has a strong potential, showing both analgesic and neuroprotective activity together with slight side effects [178,224]. Many NR1/NR2B antagonists, including ifenprodil, eliprodil and the selective and potent congeners, traxoprodil and Ro 25-6981, offer promise in preclinical models of ischemia [225][226][227][228][229].…”

Section: Selfotelmentioning

confidence: 99%

Ion Channels as Drug Targets in Central Nervous System Disorders

Waszkielewicz¹,

Gunia²,

Szkaradek³

et al. 2013

CMC

View full text Add to dashboard Cite

Ion channel targeted drugs have always been related with either the central nervous system (CNS), the peripheral nervous system, or the cardiovascular system. Within the CNS, basic indications of drugs are: sleep disorders, anxiety, epilepsy, pain, etc. However, traditional channel blockers have multiple adverse events, mainly due to low specificity of mechanism of action. Lately, novel ion channel subtypes have been discovered, which gives premises to drug discovery process led towards specific channel subtypes. An example is Na + channels, whose subtypes 1.3 and 1.7-1.9 are responsible for pain, and 1.1 and 1.2 -for epilepsy. Moreover, new drug candidates have been recognized. This review is focusing on ion channels subtypes, which play a significant role in current drug discovery and development process. The knowledge on channel subtypes has developed rapidly, giving new nomenclatures of ion channels. For example, Ca 2+ channels are not any more divided to T, L, N, P/Q, and R, but they are described as Ca v 1.1-Ca v 3.3, with even newer nomenclature 1A-1I and 1S. Moreover, new channels such as P2X1-P2X7, as well as TRPA1-TRPV1 have been discovered, giving premises for new types of analgesic drugs.

show abstract

“…A nível de membrana celular, as pesquisas têm se concentrado na tentativa de neuroregulação da apoptose cálcio induzida (Gráfico 1) (26,34,52) . Este efeito pode ser obtido pelo emprego de agentes bloqueadores do receptor glutamato NMDA (como o MK801, memantina e outros congêneres de geração mais recente) ou pelo uso de antagonistas competitivos do mesmo receptor como o selfotel (CGS19755) e outros antagonistas poliamínicos (CPS101,606) (19,26) . Outras duas possibilidades seriam através da inibição do receptor modulador (Magnésio, memantina e óxido nitroso) ou pela inibição do receptor glicina (kainato) (26) .…”

Section: Neuroproteçãounclassified

“…afetam o SNC, destacando-se a doença de Parkinson (1)(2)(3)(4)(5)(6)(7)(8)(9)(10) , acidentes vasculares cerebrais (11)(12)(13)(14)(15)(16)(17)(18)(19) e doenças degenerativas (20)(21)(22) , dentre outras.…”

unclassified